Loading

Press Releases

About Avicanna

Avicanna is a Canadian commercial-stage biopharmaceutical company established in research, development, and commercialization of evidence-based cannabinoid products for the global consumer, as well as medical and pharmaceutical market segments. Avicanna conducts its own R&D and collaborates with leading Canadian academic and medical institutions in Canada. Avicanna has established an industry leading scientific platform that includes R&D and clinical development and has led to the commercialization of over thirty proprietary products and robust pharmaceutical pipeline.

  • MyMedi.ca Medical Cannabis Care Platform Medical Cannabis Pharmacy Platform Launched August 2023
  • Medical Cannabis & RHO Phyto
  • Pharmaceutical Products
  • Aureus Santa Marta: Active Pharmaceutical Ingredients
May 14, 2024

Avicanna Reports Q1 2024 and First Positive Adjusted EBIDTA Quarter

TORONTO, May 14, 2024 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development …

May 13, 2024

Avicanna Announces Results of Study in Patients with Epidermolysis Bullosa

TORONTO, May 13, 2024 (GLOBE NEWSWIRE) – Avicanna Inc. (“Avicanna” or “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization

April 18, 2024

Avicanna Announces Closing of Non-brokered Private Placement

ORONTO, April 18, 2024 (GLOBE NEWSWIRE) – Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company …

April 10, 2024

Avicanna Announces Completion of Topical Gel Observational Real-World Evidence Study

TORONTO, February 13th, 2024 (GLOBE NEWSWIRE) – Avicanna Inc. (“Avicanna” or the “Company) …

Avicanna Reports Full Year 2023 Audited Financial Results – April 02, 2024
Avicanna Announces the Canadian Launch of 10% CBD (THC Free) Proprietary Formulation – March 27, 2024
Avicanna To Hold Full Year 2023 Earnings Conference Call – March 26, 2024
Avicanna Hosts Symposium on Cannabinoid-based Medicine – February 20, 2024
Avicanna Announces New Research Collaboration with a Multi-national European-based Pharmaceutical Company – February 15, 2024
Avicanna Obtains Its First Indication-Specific Drug Registration with Trunerox™ – February 13, 2024
Avicanna Announces Supply and Licensing Agreement with Multinational Pharmaceutical Company – February 5, 2024
Avicanna and Ease Labs Pharma Granted Commercialization Approval for Pharmaceutical Preparation in Brazil – January 30, 2024
Avicanna Announces Closing of Non-Brokered Private Placement – December 4, 2023
Avicanna Reports Q3 2023 Results – November 14, 2023
Avicanna Announces Appointment of Paul Fornazzari to Board of Directors – November 13, 2023
Avicanna To Hold Third Quarter 2023 Earnings Conference Call – November 1, 2023
Avicanna Provides Update on the Successful Launch of MyMedi.ca – October 11, 2023
Retirement of Chandra Panchal, PhD from the Board of Directors – September 01, 2023
Avicanna Reports Q2 2023 Financial Statement – August 15, 2023
Avicanna Announces Closing of Acquisition and Launch of MyMedi.ca – August 1, 2023
Avicanna is Pleased to Announce the Initial Network of Brands on the MyMedi.ca Platform – June 28 2023
Avicanna Subsidiary SMGH Exports Aureus Branded CBD and CBG Into Paraguay – July 17 2023
Avicanna Provides Corporate Update and Preliminary Q2 Results – June 28 2023
Avicanna and Medipharm Labs Expand Strategic Manufacturing Agreement for Avicanna’s Proprietary SEDDS Technology Capsules for Canadian and International markets – June 26 2023
Avicanna Sponsors New Medical Cannabis Education and Training Campaign in Canada with the Canadian Consortium for the Investigation of Cannabinoids (“CCIC”) – June 22 2023
Avicanna and Langara College Announce Cannabinoid-Based Translational Research Collaboration and NSERC Grant – June 13, 2023
Shoppers Drug Mart and Avicanna Execute Definitive Asset Purchase Agreement for Avicanna’s Acquisition of the Medical Cannabis by Shoppers BusinessMay 29, 2023
Avicanna Announces Results of Annual General and Special Meeting and Provides Corporate UpdateMay 17, 2023
Avicanna Reports Q1 2023 Financial StatementMay 16, 2023
Avicanna and Northern Green Canada Execute Master Service Agreement to Operationalize MyMedi.caMay 4, 2023
Avicanna Announces Filing of Annual Financial Statements for Year Ended December 31, 2022 April 3, 2023
Shoppers Drug Mart partners with Avicanna to transition Medical Cannabis by ShoppersMarch 28, 2023
Avicanna Announces Closing of Non-Brokered Private Placement – March 21, 2023
Avicanna Expands its Partnership with Viola Brands to the United Kingdom – February 07, 2023
Avicanna Announces Warrant and Debenture Repricing and Amendments – January 30, 2023
Avicanna Subsidiary Santa Marta Golden Hemp S.A.S. Completes First Commercial Export of feminized Cannabis Seeds from Colombia to Spain – January 17, 2023
Avicanna Announces Organizational Change in Avicanna LATAM S.A.S – December 30, 2022
Avicanna Announces Promotion of Phillip Cardella to Chief Financial Officer and Closing of Non-Brokered Private Placement – December 21 2022
Avicanna and Santé Cannabis Initiate Real-World Evidence Study on Musculoskeletal Pain and Inflammation with the RHO PhytoTM CBG Transdermal Gel Topical ProductDecember 14 2022
▪ Avicanna Commercializes ‘Influid’, a Proprietary Water-soluble technology in the Canadian Market – November 29, 2022
▪ Avicanna Reports Q3 2022 Financial Statement
November 14, 2022
Avicanna Announces Closing of Non-Brokered Private Placement November 11, 2022
Avicanna Announces Extension of Term Loan October 31, 2022
Avicanna Files Complete Patent Specifications Relating to a Novel Cannabinoid Formulation for Reducing Incidence of Seizures and Sudden Unexpected Death in Epilepsy October 20, 2022
Avicanna Introduces a New Medical Cannabis Education Online Portal, “Avicenna Academy” for Health Care Professionals October 18, 2022
Avicanna Expands its Epilepsy Research Program with a New Collaboration with the University of Toronto September 15, 2022
Avicanna Expands its Epilepsy Research Program with a New Collaboration with the University of Toronto – September 15, 2022
Avicanna Announces Results of Annual General and Special MeetingSeptember 01, 2022
Avicanna Announces Closing of Strategic Private Placement – August 17, 2022
Avicanna Reports Q2 2022 Financial StatementAugust 15, 2022
Avicanna and Ei. Ventures Enter into an Agreement to Develop and Commercialize Adaptogen NutraceuticalsJuly 20, 2022
RE+PLAY ANNOUNCES THE NBPA AS AN OFFICIAL PARTNERJuly 12, 2022
Avicanna Announces Date of Upcoming Annual General and Special Meeting of Shareholders   – July 11, 2022
Avicanna Completes its First Commercial Export of its Derma-Cosmetics Brand Pura H&W™ into the European Union – July 07, 2022
Avicanna Sells Stake in Majority-Owned Colombian Subsidiary Sativa NativaJune 24, 2022
Avicanna Completes its First Commercial Export of its Derma-Cosmetics Brand Pura H&W™ into the European Union – July 07, 2022
▪ Avicanna Sells Stake in Majority-Owned Colombian Subsidiary Sativa Nativa – June 24, 2022
Avicanna’s Subsidiary Santa Marta Golden Hemp Completes First Commercial Export of Feminized Cannabis Seeds to Lesotho – June 09, 2022
Avicanna’s Subsidiary Santa Marta Golden Hemp Completes First Commercial Export of Feminized Cannabis Seeds to LesothoMay 24, 2022
Avicanna Announces Closing of Strategic Private PlacementMay 12, 2022
Avicanna Announces Closing of Strategic Private PlacementMay 6, 2022
Avicanna Expands RHO PhytoTM Formulary with the Introduction of Cannabigerol (CBG) Products into the Canadian Market  – April 28, 2022
Avicanna Enters into Exclusive License and Supply Agreement with Major South American Pharmaceutical Company – April 28, 2022
Avicanna Enters into Exclusive License and Supply Agreement with Major South American Pharmaceutical Company  – April 13, 2022
Avicanna Expands its Derma-Cosmetics Brand Pura H&W™ into the European Union through a Partnership with Bio-Gate AGApril 5, 2022
Avicanna Announces Filing of Annual Financial Statements for Year Ended December 31, 2021 March 31, 2022
Avicanna Announces Closing of Non-Brokered Private Placement – March 31, 2022
Avicanna Enters into a Strategic Partnership with Tetra Bio-PharmaFebruary 10, 2022
Avicanna Provides Q4-2021 Results and Corporate Highlights as well as Fiscal 2022 GuidanceFebruary 02, 2022
Avicanna Announces Closing of Non-Brokered Private Placement of Convertible Debenture UnitsJanuary 28, 2022
Avicanna Enters Master Supply Agreement with Chilean Pharmaceutical Pioneer Knop Laboratorios S.A.January 14, 2022
Avicanna Announces the Appointment of Stephen Kim as Chief Legal Officer & General CounselJanuary 10, 2022
Avicanna Announces Changes to its Board of Directors Jan. 4, 2022
Avicanna Completes First Commercial Export of CBG from Colombia to Czech RepublicDec. 24, 2021
Avicanna Launches its Clinically Backed CBD Derma-cosmetics Brand, Pura H&W, in the United States in Partnership with Red White and BloomDec. 22, 2021
Avicanna and Harrington Wellness launch re+PLAY™ branded CBD topicals products in CanadaDec. 20, 2021
Avicanna to Participate in the Lytham Partners Winter 2021 Investor ConferenceDec. 10, 2021
Avicanna Files a Patent to Protect its Advanced Oral Cannabinoid Platform and its Applications for Neurological DiseasesDec. 06, 2021
Avicanna Enters into an Intellectual Property Licensing and Distribution Agreement with Established Pharmaceutical Company in ArgentinaNov. 30, 2021
Avicanna Expands its Medical Cannabis Brand RHO Phyto into the Caribbean Region with Initial Export to Barbados– Nov. 25, 2021
Avicanna Announces Filing of Interim Financial Statements for the Three-Month Period Ending September 30, 2021, Demonstrating Progressive Commercialization ResultsNov. 12, 2021
Avicanna Announces Resignation of DirectorNov. 11, 2021
Viola Brands Launches Nationwide in Canada through the Medical Cannabis by ShoppersTM online platformNov. 9, 2021
Avicanna Inc. to Host Third Quarter 2021 Investor Conference Call on November 12 and Announces Warrant Repricing Nov. 8, 2021
Avicanna Announces Management ChangeNov. 5, 2021
Avicanna´s subsidiary obtains Good Agricultural and Collection Practices (“GACP”) Certification in ColombiaNov. 4, 2021
Avicanna Completes Commercial Export of CBD Isolate and CBD Full Spectrum Psychoactive Derivatives from Colombia to ChileOct. 22, 2021
Avicanna Closes Non-Brokered Private Placement Raising $3.9 Million and Announces Warrant RepricingOct. 19, 2021
Avicanna Completes First Commercial Export of Feminized Cannabis Seeds from Colombia to Peru and ArgentinaOctober 1, 2021
Avicanna Files US Patent Application for a Novel Cannabinoid Formulation in Reducing Incidence of Seizures and Sudden Unexpected Death in EpilepsySept. 24, 2021
Avicanna Completes Registration and Commercial Export of its Evidence-Based CBD Dermacosmetics Brand, Pura Earth, in Ecuador Sept. 16, 2021
Avicanna Announces Filing of Interim Financial Statements for Period Ended June 30, 2021 and Provides Corporate UpdateSept. 10, 2021
Avicanna Announces Filing of Annual Financial Statements For Year Ended December 31, 2020Sept. 03, 2021
Avicanna Completes First Commercial Export of Aureus Branded Full Spectrum Psychoactive CBD Cannabis Extracts to BrazilAug 27, 2021
Avicanna Expands Sales of Pura Earth and RHO Phyto Branded Topicals into Alberta’s Retail ChannelsAug 24, 2021
Avicanna Enters Partnership with Heritage Cannabis Holdings Corp. to Commercialize Evidence-Based Topical Products through Heritage’s Medical Cannabis ChannelsAug 11, 2021
Avicanna Announces Partial Revocation of Cease Trade Order and Proposed FinancingAugust 3, 2021
Avicanna Completes First Commercial Export of Aureus™ Branded THC Active Pharmaceutical Ingredients to PeruAugust 3, 2021
Avicanna Completes First Commercial Export of Aureus™ Branded THC Extracts to Austria and Welcomes Colombian Government’s Progressive New Regulation on CannabisJuly 28, 2021
Avicanna Announces Change of AuditorJuly 19, 2021
Avicanna and Bio-Gate Complete First Phase of Development on Cannabidiol (CBD) and MicroSilver BG™ Based Skin Care Products for Global Commercialization– June 29, 2021
Avicanna Announces Results of Annual General Meeting and Provides Corporate Update– June 24, 2021
Avicanna Expands The Canadian RHO Phyto Product Offerings With The Addition Of THC-Free High CBD Oral And Sublingual Formulation Across Medical And Adult Use Channels– June 15, 2021
Avicanna Announces Mailing of Management Information Circular and Proposed Board Changes– June 3, 2021
Avicanna’s Evidence-Based and Dermatologist Tested CBD Derma-Cosmetic Brand Pura Earth™ to be Launched in Adult-Use and Medical Channels Across Canada in Q2 2021.– May 26, 2021
Avicanna Makes RHO Phyto™ Medical Cannabis Products Available In Canadian Hospital Pharmacies Through Agreement with Sunnybrook Hospital – May 6, 2021
Avicanna Provides Bi-Weekly Update On Status Of Management Cease Trade Order – April 26, 2021
Avicanna Announces Receipt of Management Cease Trade Order and Provides Bi-Weekly Status Update – April 12, 2021
Avicanna Announces Late Filing of Financial Statements and Application for Management Cease Trade Order – March 29, 2021
Avicanna Closes Non-Brokered Private Placement Raising $5.6 Million – Mar 4, 2021
Avicanna Announces Exercise And Closing Of Over-Allotment Option – Dec 31, 2020
Avicanna Announces Closing of Public Offering of Units – Dec 8, 2020
Avicanna Announces Overnight Marketed Public Offering of Units – Nov 12, 2020
Avicanna Reports Third Quarter 2020 Financial Results and Provides Corporate Update – Nov 12, 2020
Avicanna Closes Non-Brokered Private Placement Raising $2.7 Million – Aug 18, 2020
Avicanna Reports Second Quarter 2020 Financial Results and Provides Corporate Update – Aug 17, 2020
Avicanna Reports First Quarter 2020 Financial Results and Provides Corporate Update – May 25, 2020
Avicanna Closes Non-Brokered Private – Placement with Group of Strategic Investors and Announces Warrant Re-Pricing – April 21, 2020
Avicanna Reports Fourth Quarter 2019 Financial Results and Provides Corporate Update – April 15, 2020
Avicanna Closes First Tranche of Private Placement – January 24, 2020
Avicanna Reports Third Quarter 2019 Financial Results – Nov. 14, 2019
Avicanna Completes its First Exportation of Cannabinoids from Colombia to Canada for Scientific Purposes – Aug 23, 2019
Avicanna Reports Second Quarter 2019 Financial Results – Aug 14, 2019
Avicanna Commences Trading on the TSX Under the Symbol “AVCN” – July 18, 2019
Avicanna Announces TSX Listing Date – July 16, 2019
Avicanna Announces Receipt for Final Prospectus and Conditional Approval for Listing on the TSX – July 10, 2019
Avicanna Closes Oversubscribed $22.1 Million Special Warrant Offering – April 18, 2019
Avicanna Announces Filing of Preliminary Prospectus – January 21, 2019
Avicanna Inc. Acquires 60% Stake in Colombian Medical Marijuana Firm Santa Marta Golden Hemp – August 16, 2018
Avicanna Completes 2nd Equity Financing & Welcomes New Strategic Shareholder – January 29, 2018
Avicanna Closes its First Equity Financing and Announces its Residency at Johnson & Johnson Innovation, JLABS @ Toronto – May 26, 2017

avica_white

480 University Ave, Suite 1502
Toronto, ON M5G 1V2
Canada

Want to stay up to date? Subscribe to receive email updates.

           
© 2017-2019 Avicanna Inc. All Rights Reserved.
Subscribe
SUBSCRIBE NOW

Sign up and join our Newsletter  

Stay updated with all latest
updates and news.
close-link